Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
2.
Am J Dermatopathol ; 45(6): 355-370, 2023 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-37191371

RESUMEN

BACKGROUND: Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome is a rare, hereditary, autoinflammatory disease. However, there are few cases reported in the literature. Therefore, we conduct this systematic review to summarize current evidence. METHODS: We conducted a systematic search in July 2021 using 11 different electronic databases. The included articles were screened according to our inclusion and exclusion criteria and assessed using an appropriate quality assessment tool. Then, the relevant data were extracted and summarized in tables accordingly. Each step of the previous one was done by 3 independent reviewers, and the conflicts were resolved by discussion and sometimes by counseling a senior member. RESULTS: The final included studies were 18 articles with 34 cases (mean age = 8 years, male/female = 19/15). The most reported symptoms and signs were fever 97.1%, erythematous plaques 76.5%, arthralgia 67.6%, hepatomegaly 61.8%, violaceous hue 61.8%, lipodystrophy in extremities 53.1% in addition to low weight and height. Rare features were reported too. The laboratories were not specific, which may be explained by a systemic inflammatory response. Vasculitis was the dominant feature in the skin biopsy, whereas the calcification in the basal ganglia was a prominent sign in many cases. CONCLUSIONS: Fever, skin lesions, and systemic inflammatory response were the prominent features of chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome. The clinical picture is the main guide in addition to the pathological findings. Mutation detection is the confirmatory test. Prednisolone is the most effective reported treatment for acute presentations in the literature.


Asunto(s)
Dermatitis , Lipodistrofia , Enfermedades de la Piel , Síndrome de Sweet , Humanos , Masculino , Femenino , Niño , Síndrome de Sweet/diagnóstico , Síndrome de Sweet/tratamiento farmacológico , Síndrome de Sweet/patología , Enfermedades de la Piel/diagnóstico , Enfermedades de la Piel/tratamiento farmacológico , Enfermedades de la Piel/patología , Lipodistrofia/diagnóstico , Lipodistrofia/genética , Lipodistrofia/patología , Fiebre/diagnóstico , Enfermedad Crónica , Síndrome de Respuesta Inflamatoria Sistémica
3.
Rev Med Virol ; 31(6): e2288, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34472152

RESUMEN

SARS Coronavirus-2 is one of the most widespread viruses globally during the 21st century, whose severity and ability to cause severe pneumonia and death vary. We performed a comprehensive systematic review of all studies that met our standardised criteria and then extracted data on the age, symptoms, and different treatments of Covid-19 patients and the prognosis of this disease during follow-up. Cases in this study were divided according to severity and death status and meta-analysed separately using raw mean and single proportion methods. We included 171 complete studies including 62,909 confirmed cases of Covid-19, of which 148 studies were meta-analysed. Symptoms clearly emerged in an escalating manner from mild-moderate symptoms, pneumonia, severe-critical to the group of non-survivors. Hypertension (Pooled proportion (PP): 0.48 [95% Confident interval (CI): 0.35-0.61]), diabetes (PP: 0.23 [95% CI: 0.16-0.33]) and smoking (PP: 0.12 [95% CI: 0.03-0.38]) were highest regarding pre-infection comorbidities in the non-survivor group. While acute respiratory distress syndrome (PP: 0.49 [95% CI: 0.29-0.78]), (PP: 0.63 [95% CI: 0.34-0.97]) remained one of the most common complications in the severe and death group respectively. Bilateral ground-glass opacification (PP: 0.68 [95% CI: 0.59-0.75]) was the most visible radiological image. The mortality rates estimated (PP: 0.11 [95% CI: 0.06-0.19]), (PP: 0.03 [95% CI: 0.01-0.05]), and (PP: 0.01 [95% CI: 0-0.3]) in severe-critical, pneumonia and mild-moderate groups respectively. This study can serve as a high evidence guideline for different clinical presentations of Covid-19, graded from mild to severe, and for special forms like pneumonia and death groups.


Asunto(s)
COVID-19/patología , Tos/patología , Disnea/patología , Fatiga/patología , Fiebre/patología , SARS-CoV-2/patogenicidad , Antivirales/uso terapéutico , COVID-19/mortalidad , COVID-19/virología , Comorbilidad , Tos/tratamiento farmacológico , Tos/mortalidad , Tos/virología , Diabetes Mellitus/diagnóstico , Diabetes Mellitus/fisiopatología , Disnea/tratamiento farmacológico , Disnea/mortalidad , Disnea/virología , Fatiga/tratamiento farmacológico , Fatiga/mortalidad , Fatiga/virología , Fiebre/tratamiento farmacológico , Fiebre/mortalidad , Fiebre/virología , Humanos , Hipertensión/diagnóstico , Hipertensión/fisiopatología , Factores Inmunológicos/uso terapéutico , Pronóstico , Síndrome de Dificultad Respiratoria/diagnóstico , Síndrome de Dificultad Respiratoria/fisiopatología , Índice de Severidad de la Enfermedad , Fumar/fisiopatología , Análisis de Supervivencia , Tratamiento Farmacológico de COVID-19
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...